watson-ecole man. >> thank you very much. i want to follow up on mr. carter's line of questioning.i don't understand now. before you acquired the drug, was there a problem with access to it? >> yes, there was. >> so your desire to acquire the plug and there was a problem with access, does it mean people suffering from infections associated with hiv/aids didn't have access to it the way it needed it? >> if june, three months before we acquired the asset the previous manufacturer went to a special ti distribution model and closed distribution. that was three months before we purchased it. after -- >> what was going on before those three months. was it the closed distribution? >> no. it was broader. >> was that as a result of it shall in an 'tis tags of your company buying this drug? >> absolutely not. there is proof that the arrangement originated not with the previous manufacturer but the manufacturer before that. >> yet walgreens which is the closed distribution, right? >> yes. >> walgreens informed you all they were concerned about access to patients, other pharmacies, et cetera.